Please assess the completion status of the following clinical trial:

Trial Title: The Role of Trimetazidine on Right Ventricle Function in Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pre-capillary Pulmonary Hypertension patients assessed by right heart catheterization~* Signed informed consent~Exclusion Criteria:~* Patient belonging to post-capillary, Isolated post-capillary, or combined post -capillary and pre-capillary pulmonary hypertension according to 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.~* Moderate to severe chronic pulmonary obstructive disease~* Right Ventricular Ejection Fraction \> 45% assessed by cardiac magnetic resonance.~* Documented left ventricular dysfunction with left ventricular ejection fraction \< 50% assessed by cardiac magnetic resonance.~* Severe renal impairment (Serum creatinine \> 2.5 mg/dL, eGFR \< 30ml/min/1.73 m\^2, or routine dialysis treatment).~* Malignant arrhythmia such as total atrioventricular block or ventricular fibrillation or unstable ventricular tachycardia.~* Patients who are receiving or have been receiving any investigational drugs within 1 month before the baseline visit~* Acute or chronic impairment (other than dyspnea) limiting the ability to comply with study requirements~* Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study requirements~* Females who are lactating or pregnant or those who plan to become pregnant during the study~* Known Parkinson disease~* Known hypersensitivity to any of the drug formulation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sugar pill (Type: PLACEBO_COMPARATOR): The participant will received placebo oral capsule bid for 3 months on top of their regular PAH specific therapy.
- trimetazidine (Type: EXPERIMENTAL): The participant will received trimetazidine 35 mg bid for 3 months on top of their regular PAH specific therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).